Etodolac

Etodolac
Clinical data
AHFS/Drugs.comMonograph
MedlinePlusa692015
Routes of
administration
By mouth
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only
Pharmacokinetic data
Protein binding100%
Metabolismliver
Elimination half-life7.3 ± 4.0 hours
Excretionrenal
Identifiers
  • (RS)-2-(1,8-Diethyl-4,9-dihydro-3H-pyrano[3,4-b]indol-1-yl)acetic acid
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.157.848
Chemical and physical data
FormulaC17H21NO3
Molar mass287.359 g·mol−1
3D model (JSmol)
Melting point145 to 148 °C (293 to 298 °F)
Solubility in water3.92e-02 mg/mL [ALOGPS] mg/mL (20 °C)
  • CCc2cccc3c1CCOC(CC)(CC(=O)O)c1[nH]c23
  • InChI=1S/C17H21NO3/c1-3-11-6-5-7-12-13-8-9-21-17(4-2,10-14(19)20)16(13)18-15(11)12/h5-7,18H,3-4,8-10H2,1-2H3,(H,19,20) checkY
  • Key:NNYBQONXHNTVIJ-UHFFFAOYSA-N checkY
  (verify)

Etodolac is a nonsteroidal anti-inflammatory drug (NSAID).

It was patented in 1971 and approved for medical use in 1985. It was approved in the U.S. in 1991.

In 2023, it was the 296th most commonly prescribed medication in the United States, with more than 400,000 prescriptions.